CS585 does not alter hemostasis. (A) WT mice were treated with vehicle or CS585 (0.5 or 6 mg/kg), and bleeding time of the tail was assessed (n = 10). Data represent mean ± SEM. One-way ANOVA with Dunnett correction. (B-E) Human whole blood was treated with the vehicle, CS585 (100 nM or 1 μM), rivaroxaban (250 ng/mL), or CS585 (100 nM or 1 μM) + rivaroxaban (250 ng/mL). Coagulation parameters were assessed using TEG (n = 4). (B) Reaction time is the time to initial fibrin thread formation (minutes). (C) Maximum amplitude and the maximum strength of the clot (mm). (D) K time represents the time until the clot reaches a strength of 20 mm (minutes). (E) α angle, rate of clot formation (degree). One-way ANOVA with Dunnett correction. (F) Representative tracing of the coagulation parameters measured in panels B-E. (G) The maximum rate of thrombin generation was measured by TEG using a velocity curve that graphs the clot strength over time (n = 4). One-way ANOVA with Dunnett correction. (H) Representative tracing of the velocity curve used to calculate the rate of thrombin generation. ∗P < .05; ∗∗P < .01; ∗∗∗P < .001; ∗∗∗∗P < .0001. ns, nonsignificant.